Novel molecule may help overcome the devastating symptoms of Duchenne muscular dystrophy

In a new study published in The FASEB Journal, investigators demonstrated the potential of a molecule that may help overcome some of the devastating symptoms of Duchenne muscular dystrophy (DMD), the most common life-limiting congenital neuromuscular disorder. The agent promotes the activity of AMP-activated protein kinase (AMPK), an important fuel-sensing enzyme that is present in all mammalian cells.

Previous research has shown that stimulating AMPK can mitigate the dystrophy-;or wasting-;of muscles, but AMPK activators have failed to reach the clinic due to either their lack of potency or toxic off-target effects.

In this latest work, scientists utilized a next generation oral AMPK agonist called MK-8722 and showed that when given as a single dose to mice with muscular dystrophy, it triggered signaling pathways associated with improved muscle health.

Additional studies are needed to test the chronic administration of such next-generation AMPK activators in dystrophic animals to further examine their safety and effectiveness.

Our work highlights the therapeutic potential of this novel class of AMPK activators in DMD, as well as in other neuromuscular diseases. We hope that these findings can be extended to other novel AMPK agonists that are currently being investigated in ongoing clinical trials. If so, repositioning these therapies may pose as a cost-effective and efficacious method for the treatment of DMD regardless of the specific disease-causing mutation."

Sean Ng, MSc, lead author, PhD candidate, of McMaster University, Canada

Journal reference:

Ng, S.Y., et al. (2023) Acute, next-generation AMPK activation initiates a disease-resistant gene expression program in dystrophic skeletal muscle. The FASEB Journal.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Universal approach could potentially expand CAR T cell therapy to all blood cancers